Company / Revenue per Share
Travere Therapeutics, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$5.61
FY2025
5-year range
$1.75 / $5.61
FY2021-FY2025
Trend
+81.4%
vs FY2024
Sector context
#63 of 154
Health Care
What the data says
At $5.61, Travere Therapeutics, Inc.'s revenue per share ranks #63 of 154 in the Health Care sector. Revenue per Share has increased for 3 consecutive years, from $1.75 in FY2022 to $5.61 in FY2025.
Based on SEC 10-K filings.
5.61 in FY2025 with a 5-year CAGR of +8.0%.
Improved from $2.26 to $5.61 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +47.4%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Sector benchmark
#63 of 154 in Health CareTop 41% of 154This company $5.61 Sector average $15.09
▼
-62.8% below sector average
Key checks
Key Insights
- Travere Therapeutics, Inc.'s revenue per share has grown for 3 consecutive years.
- In FY2025, revenue per share increased 81.4% year-over-year.
- Ranks #63 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.61 | +81.4% |
| FY2024 | $3.09 | +37.0% |
| FY2023 | $2.26 | +29.0% |
| FY2022 | $1.75 | -47.8% |
| FY2021 | $3.36 | -12.0% |
| FY2020 | $3.81 | +1.8% |
| FY2019 | $3.74 | +10.3% |
| FY2018 | $3.39 | +28.8% |
| FY2017 | $2.64 | +240.7% |
| FY2016 | $0.77 | -79.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026